Complete Response With Immunotherapy: A Case of Metastatic Bladder Cancer

Balraj Singh, Parminder Kaur, Sachin Gupta, Nirmal Guragai, Michael Maroules

Research output: Contribution to journalArticlepeer-review

Abstract

Bladder cancer is the most common urinary tract malignancy. Platinum-based chemotherapy is the first line of treatment in locally advanced or metastatic bladder cancer. Immunotherapy has become a novel therapy option in a broad variety of malignancies including bladder cancer. Immunotherapy is approved as first line of treatment in patients who are ineligible for platinum-based chemotherapy and second-line treatment for metastatic urothelial cancer who progressed after platinum-based treatments. We present the case of an 83-year-old female with metastatic bladder cancer who was chemotherapy ineligible and had complete response with immune checkpoint inhibitor pembrolizumab.

Original languageEnglish (US)
JournalJournal of Investigative Medicine High Impact Case Reports
Volume9
DOIs
StatePublished - 2021

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Safety, Risk, Reliability and Quality
  • Safety Research

Cite this